Last reviewed · How we verify
BPM31510 Nanosuspension Injection
BPM31510 is a nanosuspension formulation of buparlisib that inhibits phosphatidylinositol 3-kinase (PI3K) to block tumor cell proliferation and survival signaling.
BPM31510 is a nanosuspension formulation of buparlisib that inhibits phosphatidylinositol 3-kinase (PI3K) to block tumor cell proliferation and survival signaling. Used for Advanced solid tumors (Phase 2 development).
At a glance
| Generic name | BPM31510 Nanosuspension Injection |
|---|---|
| Also known as | Ubidecarenone, USP |
| Sponsor | BPGbio |
| Drug class | PI3K inhibitor |
| Target | PI3K (phosphatidylinositol 3-kinase) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BPM31510 is a pan-PI3K inhibitor designed to improve the bioavailability and tolerability of buparlisib through nanosuspension technology. By inhibiting PI3K across multiple isoforms, it disrupts the PI3K/AKT/mTOR pathway, which is frequently hyperactivated in cancer cells. The nanosuspension formulation aims to enhance drug delivery and reduce gastrointestinal toxicity associated with the parent compound.
Approved indications
- Advanced solid tumors (Phase 2 development)
Common side effects
- Hyperglycemia
- Diarrhea
- Rash
- Nausea
Key clinical trials
- A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) (PHASE2)
- BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients (PHASE2)
- BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors (PHASE1)
- Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older Adults With Sarcopenia (EARLY_PHASE1)
- BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab (PHASE1)
- Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa (PHASE1)
- A Safety Study of Orally Administered BPM31510 in Healthy Subjects (PHASE1)
- A Safety Study of Orally Administered BPM31510 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BPM31510 Nanosuspension Injection CI brief — competitive landscape report
- BPM31510 Nanosuspension Injection updates RSS · CI watch RSS
- BPGbio portfolio CI